Latest studies
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
This study is testing a new medicine, NNC0487-0111, for people with type 2 diabetes. It's looking at different ways to take the medicine (once a week shot or once a day pill) to see how safe and effective it is at controlling blood sugar.
Type 2 DiabetesRomania - RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
Chronic Hepatitis DRomania - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerRomania - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
This study compares two versions of a 15mg upadacitinib tablet in healthy adults. It's to see if a new tablet works the same way in the body as an existing one, for conditions like rheumatoid arthritis and Crohn's disease.
Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritisRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma
This study is testing a new medicine, Atuliflapon, for adults whose moderate-to-severe asthma isn't well controlled by their usual treatments. We want to see if it reduces asthma flare-ups and improves breathing, compared to a dummy pill, over 12 weeks.
Moderate-to-Severe Uncontrolled AsthmaRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
This study is comparing a new medicine, JPB898, to a licensed cancer drug called Opdivo. Both are used with another drug, Yervoy, to treat advanced melanoma, a serious type of skin cancer. The aim is to see if JPB898 works just as well and is as safe as Opdivo.
Advanced (unresectable/metastatic) melanomaRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
This study is checking a new treatment called Immukine alongside usual care for a serious fungal infection in the blood called candidemia. Researchers want to see if it makes people get better faster and how safe it is.
CandidemiaRomania - RecruitingPHASE3
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This study is for people with chronic Hepatitis D (HDV) whose current medicine, bulevirtide, isn't fully controlling the virus. It will test if a new combination of medicines, tobevibart and elebsiran, works better. It's a key step in finding more effective treatments.
Viral HepatitisRomania - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
Interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding trial of Lu AG09222 for the prevention of migraine in participants with episodic and chronic migraine. Lundbeck trial no: 20297A
This study is testing a new medicine, Lu AG09222, to see if it can help prevent migraines. It's for people who get migraines often, including those with episodic (comes and goes) and chronic (very frequent) migraine. Researchers want to find the best dose to reduce migraine days.
MigraineRomania - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.
This study compares two different versions of a medicine called lamotrigine, used for epilepsy and bipolar disorder. Researchers want to see if a new tablet works the same way as an existing one, by giving single doses to healthy adult volunteers.
Bipolar disorder, EpilepsyRomania - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection
This study is testing a new medicine, ABI-4334, for people with long-term hepatitis B. It will check if the medicine is safe, how it works in the body, and if it helps fight the virus. Researchers want to find the best dose.
chronic hepatitis B virus infection (cHBV)Romania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy
This study compares two ways of giving a medicine called Nivolumab for advanced kidney cancer. One way is an injection under the skin, and the other is a drip into a vein. Doctors want to see if the injection works just as well and is safe for patients.
Metastatic Clear Cell Renal Cell CarcinomaRomania - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVRomania - AuthorisedHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec® (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo – SP, CNPJ: 56.994.502/0001-30, Brazilian Industry, in healthy adult, human subjects under fed condition.
This study compares a new 400mg imatinib tablet from Sun Pharmaceutical Industries with the original Glivec 400mg tablet. We want to check if they work the same way in healthy adults after a meal. This is important for treating leukaemia.
Acute Lymphoblastic Leukemia (Ph+ ALL), (Ph+) Chronic Myeloid LeukemiaRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
This study is looking for new ways to help adults with severe asthma that isn't well controlled. It tests a new drug, GB-0895, alongside their usual asthma medicine, to see if it reduces severe asthma attacks.
severe uncontrolled asthmaRomania - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung Cancer, HER2 MutationRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)
This study is comparing a new medication called FYB206 to a commonly used lung cancer drug, Keytruda. We want to see if FYB206 works just as well and is as safe for people with a certain type of advanced non-small cell lung cancer when given with chemotherapy.
NSCLCRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Batoclimab, for adults with a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if this medicine can stop CIDP symptoms from getting worse, compared to a dummy medicine. It's an important step to find better treatments.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Romania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis (DRTB-HDT).
This study is testing two new medicines alongside regular treatment for a type of tough-to-treat lung infection called rifampicin-resistant tuberculosis. Researchers want to see if these new medicines improve recovery, reduce the infection, and are safe to use.
Multidrug rezistant pulmonary tuberculosisRomania - Active not recruitingPHASE3
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study looks at new drug combinations (fianlimab with cemiplimab) versus a standard drug (pembrolizumab) to see if they can stop melanoma from coming back after surgery. It's for people at high risk of their melanoma returning.
MelanomaRomania - Active not recruitingPHASE3
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
This study compares new drug combinations (dostarlimab and niraparib) with standard care for women newly diagnosed with advanced ovarian cancer. It aims to see if these new treatments can stop the cancer from growing for longer.
Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal CarcinomaRomania - Active not recruitingPHASE3
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
This study investigates a new drug, elafibranor, for adults with Primary Biliary Cholangitis (PBC). It aims to see if elafibranor can improve liver health in people whose current treatment isn't working well or who can't tolerate it. It compares elafibranor to a dummy treatment.
Primary Biliary CholangitisRomania - AuthorisedHuman Pharmacology (Phase I)- Other
A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in mild asthmatics aged 18 to 65 inclusive.
This study is looking at a new type of inhaler for people with mild asthma, aged 18 to 65. We want to see if the new inhaler works as well as the current ones. It compares a new gas used in the inhaler with the one currently used.
Mild AsthmaRomania - Recruiting
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
This study looks at how a new scoring system helps doctors decide the best treatment for broken bones in the back caused by osteoporosis. It compares how well patients do when doctors follow the score's advice versus when they choose a different path.
Osteoporotic FracturesOsteoporosisRomania - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesRomania - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
Breast Cancer; HER2-positive; MetastaticRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
This study looks at new treatments for advanced ovarian cancer. It combines standard chemotherapy with newer drugs, durvalumab and bevacizumab, and then adds olaparib. We want to see if this combination helps patients live longer without their cancer growing.
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancerRomania - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsRomania - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
Breast CancerRomania - AuthorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.
This study is testing a new medicine, CR-001, for adults with certain advanced or spreading cancers. It aims to find a safe and effective dose, understand how the body uses the medicine, and see if it can shrink tumors or slow their growth.
Locally Advanced or Metastatic Solid TumorsRomania - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
Various Advanced CancerRomania - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
Non-Small Cell Lung CancerRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)
This study, called PREVAIL, is testing new medicines for people with long-term Hepatitis B. It aims to see how well these new treatments can reduce the virus in the body and remove a specific marker of the infection.
Chronic Hepatitis B Virus (HBV) InfectionRomania - Not yet recruitingPHASE3
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
This study is for people who were in a previous trial for a medicine called anifrolumab (Saphnelo) and found it helpful. It lets you keep taking the medicine to see if it continues to work and monitor your safety.
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus ErythematosusRomania - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisRomania - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/or with Mild Cirrhosis
This study is testing a new medicine, ALE.F02, in adults with advanced liver scarring or early-stage liver disease. It aims to understand how the body uses the medicine, comparing it to a dummy treatment, to see if it could help. This is an early trial to check its effects and safety.
Advanced liver fibrosis and/or mild liver cirrhosisRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-Blind, Oral, Placebo-Controlled, Multiple-Dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
This study is testing a new medicine, Endoxifen, for people with Bipolar I Disorder. Researchers want to see if it helps improve symptoms of mania and is safe to use. It compares Endoxifen to a look-alike dummy pill in adults.
Bipolar I DisorderRomania - RecruitingPHASE3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
This study looks at a new drug, zolbetuximab, alongside usual treatments for stomach or gullet cancer that has spread or can't be removed. It aims to see if this combination helps people live longer by targeting specific proteins on cancer cells.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) AdenocarcinomaRomania - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants with Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
This study looks at a new medicine called AZD4144 in people with severe kidney problems, those on dialysis, and healthy volunteers. It checks how the body handles the medicine, if it's safe, and if it causes any side effects. It's an early-stage study.
Healthy Volunteers, Renal Impairment and End Stage Kidney DiseaseRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection
This study is checking a new medicine called Imdusiran alongside an existing one, Durvalumab (Imfinzi), for people with long-term Hepatitis B. Researchers want to see if this combination is safe, how well people tolerate it, and how it affects the body.
Chronic HBV InfectionRomania - Active not recruitingPHASE2
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
This study is looking for the right dose of a new medicine, GSK5784283, for adults aged 18 to 75 with asthma that isn't fully controlled by their current treatments. It aims to see how it affects breathing and overall asthma control.
AsthmaRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study is testing a new combination inhaler for people with a lung condition called COPD. It compares a new three-in-one inhaler to an existing two-in-one inhaler over one year to see which works better and is safer for breathing and overall health.
Chronic obstructive pulmonary disease (COPD)Romania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care
This study is testing a new medicine called Enpatoran for people with lupus that affects their whole body or their skin. Researchers want to see if it's safe and helps improve symptoms compared to a dummy drug, and find the best dose.
Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)Romania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer (BR31)
This study is looking at a new drug called durvalumab (also known as MEDI4736) for people who have had surgery for a certain type of lung cancer. It aims to see if the drug can stop the cancer from coming back, especially in those with specific cancer markers.
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patientsRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).
Moderate to Severe Plaque PsoriasisRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
This study is looking into a new medication, JNJ-67953964, to help stop depression from coming back in people who also feel unable to experience pleasure. It compares this new drug with a dummy pill, alongside standard antidepressant treatment, to see how well it works.
Major Depressive Disorder (MDD) with Moderate-to-severe AnhedoniaRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (ADVANCE Outcomes)
This study is looking at a new medicine called Ralinepag for a lung condition called pulmonary arterial hypertension (PAH). It wants to see if Ralinepag can help patients feel better and prevent their condition from getting worse over time.
Pulmonary arterial hypertension (PAH)Romania - Not yet recruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisRomania - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerRomania